Sandoz, a subsidiary of Swiss pharmaceutical giant Novartis AG, has agreed to pay US$195 million to avoid trial on charges it conspired to fix the prices of generic drugs, US prosecutors announced on Monday.
The US Department of Justice last year accused Sandoz along with 19 other companies of colluding to artificially inflate the price of about 100 treatments, ranging from non-steroidal anti-inflammatory to drugs for a wide range of diseases.
The price of the treatments multiplied by as much as 10 times, according to the complaint filed in federal court in Connecticut.
“The company agreed to pay a US$195 million criminal penalty and admitted that its sales affected by the charged conspiracies exceeded US$500 million,” the department said in a statement, adding that the misconduct occurred between 2013 and 2015.
“Under the deferred prosecution agreement, Sandoz has agreed to cooperate fully” with the ongoing criminal investigation, it said.
Former Sandoz executive Hector Armando Kellum has pleaded guilty to unspecified charges stemming from the investigation, the department said.
Sandoz had rejected the charges at the time, but on Monday issued a statement admitting “misconduct.”
“We take seriously our compliance with antitrust laws, and in reaching today’s resolution we are not only resolving historical issues, but also underscoring our commitment to continually improving our compliance and training programs, and evolving our controls,” Sandoz president Carol Lynch said.
“We are disappointed that this misconduct occurred in the face of our clear antitrust compliance policies and multiple trainings — and in full contravention of the company’s values,” she said. “Individuals implicated in the underlying conduct are no longer employed by the company.”
Sandoz said it was also negotiating with the department’s civil division to resolve “potential related claims,” and has put aside US$185 million for that.
Other companies accused in the complaint were Israel’s Teva Pharmaceutical Industries Ltd and US-based Mylan Laboratories Inc.
The department said that two other unnamed companies charged in the investigation had reached agreements with prosecutors similar to that accorded to Sandoz, in which prosecution was suspended in exchange for cooperation.
To many, Tatu City on the outskirts of Nairobi looks like a success. The first city entirely built by a private company to be operational in east Africa, with about 25,000 people living and working there, it accounts for about two-thirds of all foreign investment in Kenya. Its low-tax status has attracted more than 100 businesses including Heineken, coffee brand Dormans, and the biggest call-center and cold-chain transport firms in the region. However, to some local politicians, Tatu City has looked more like a target for extortion. A parade of governors have demanded land worth millions of dollars in exchange
An Indonesian animated movie is smashing regional box office records and could be set for wider success as it prepares to open beyond the Southeast Asian archipelago’s silver screens. Jumbo — a film based on the adventures of main character, Don, a large orphaned Indonesian boy facing bullying at school — last month became the highest-grossing Southeast Asian animated film, raking in more than US$8 million. Released at the end of March to coincide with the Eid holidays after the Islamic fasting month of Ramadan, the movie has hit 8 million ticket sales, the third-highest in Indonesian cinema history, Film
Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue jumped 48 percent last month, underscoring how electronics firms scrambled to acquire essential components before global tariffs took effect. The main chipmaker for Apple Inc and Nvidia Corp reported monthly sales of NT$349.6 billion (US$11.6 billion). That compares with the average analysts’ estimate for a 38 percent rise in second-quarter revenue. US President Donald Trump’s trade war is prompting economists to retool GDP forecasts worldwide, casting doubt over the outlook for everything from iPhone demand to computing and datacenter construction. However, TSMC — a barometer for global tech spending given its central role in the
Alchip Technologies Ltd (世芯), an application-specific integrated circuit (ASIC) designer specializing in server chips, expects revenue to decline this year due to sagging demand for 5-nanometer artificial intelligence (AI) chips from a North America-based major customer, a company executive said yesterday. That would be the first contraction in revenue for Alchip as it has been enjoying strong revenue growth over the past few years, benefiting from cloud-service providers’ moves to reduce dependence on Nvidia Corp’s expensive AI chips by building their own AI accelerator by outsourcing chip design. The 5-nanometer chip was supposed to be a new growth engine as the lifecycle
RSS